Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials
source: pixabay.com

Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials

In a press release from Sanofi, a global biopharmaceutical company, the company's experimental therapy candidate olipudase alfa has demonstrated the ability to substantially improve spleen volume and lung function in…

Continue Reading Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials
New Research Will Target Tau’s Role in Alzheimer’s Disease
source: pixabay.com

New Research Will Target Tau’s Role in Alzheimer’s Disease

Researchers from Rensselaer Polytechnic Institute have been conducting research on tau proteins, specifically how it spreads from cell to cell. According to an article in Newswise, this team of researchers…

Continue Reading New Research Will Target Tau’s Role in Alzheimer’s Disease
New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
source: pixabay.com

New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease

  In October 2020, Arrowhead Pharmaceuticals ("Arrowhead") announced a new collaboration and licensing agreement with global biopharmaceutical company Takeda Pharmaceutical Company Limited ("Takeda"). Together, the pair will develop and commercialize…

Continue Reading New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
source: pixabay.com

The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment

According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…

Continue Reading The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension
https://pixabay.com/photos/animals-lemurs-wildlife-zoo-monkey-1010643/

First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension

New Trial A Phase 1A trial for GMA301 was completed this year in Australia for pulmonary arterial hypertension (PAH). This trial demonstrated a positive safety profile for a range of…

Continue Reading First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension